search
Back to results

Hemodynamic Safety of Levobupivacaine vs Bupivacaine in Patients Over 65 Years Undergoing Hip Surgery

Primary Purpose

Hip Fractures, Hemodynamic Stability

Status
Recruiting
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
Levobupivacaine Hydrochloride 0.5%
Isobaric bupivacaine 0.5%
Sponsored by
Hospital Clínico Universitario de Valencia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hip Fractures focused on measuring Hip fracture, Subarachnoid block

Eligibility Criteria

65 Years - 120 Years (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men and Women over 65 years
  • Who meet the requirements in the pre-anesthetic to be treated with spinal anesthesia with levobupivacaine or bupivacaine, both with fentanyl,
  • Fitness: from I to IV, according to the American Society of Anesthesiologists (ASA),
  • Weight> 40 kg,
  • Height> 140 cm,
  • Body mass index (BMI) <50 kg/m2,
  • Pathology cardiovascular, respiratory, renal and endocrine-metabolic,
  • Provide written informed consent

Exclusion Criteria:

  • Patients with uncontrolled hypertension (non-invasive systolic blood pressure> 180 mmHg and / or non-invasive diastolic blood pressure > 110mmHg),
  • HR> 120 bpm,
  • SpO2 <90% on arrival in the operating room and the contraindication to perform neuraxial anesthesia (patient refusal, infection at the site of puncture or lancing different, neuromuscular degenerative disease, hypovolemia, coagulopathy or anticoagulant therapy, morbid obesity, and extreme increase in intracranial pressure).

Sites / Locations

  • Hospital Clínico UniversitarioRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Levobupivacaine Hydrochloride 0,5%

isobaric bupivacaine 0,5%

Arm Description

The doses used of Levobupivacaine Hydrochloride 0.5% will be 6 mg and the dose of fentanyl 10 μg.

The doses used of isobaric bupivacaine will be 6 mg and the dose of fentanyl 10 μg.

Outcomes

Primary Outcome Measures

Compare hemodynamic effects from invasive systolic pressure, invasive diastolic pressure and mean blood pressure.
The measurement of invasive systolic pressure and invasive diastolic pressure and mean blood pressure mesured in mmHg.
Compare hemodynamic effects from heart rate.
The measurement of heart rate in beats per minute.

Secondary Outcome Measures

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Adverse events include adverse cardiovascular and respiratory rate, events related to both surgical and anesthetic techniques.

Full Information

First Posted
May 28, 2018
Last Updated
March 30, 2022
Sponsor
Hospital Clínico Universitario de Valencia
search

1. Study Identification

Unique Protocol Identification Number
NCT03843970
Brief Title
Hemodynamic Safety of Levobupivacaine vs Bupivacaine in Patients Over 65 Years Undergoing Hip Surgery
Official Title
Hemodynamic Safety of Isobaric Levobupivacaine Versus Isobaric Bupivacaine for Subarachnoid Anesthesia in Patients Over 65 Years Undergoing Hip Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 14, 2018 (Actual)
Primary Completion Date
May 31, 2023 (Anticipated)
Study Completion Date
July 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Clínico Universitario de Valencia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The altered hemodynamics, and therefore the arterial hypotension is the most prevalent adverse effect after subarachnoid anesthesia. The objective of the study was to determine the exact role of local anesthetic selection underlying spinal anesthesia-induced hypotension in the elderly patient. We conducted a descriptive, interventional pilot study to assess the hemodynamic impact of subarachnoid anesthesia with isobaric levobupivacaine versus isobaric bupivacaine for hip fracture surgery.
Detailed Description
Objective of the trial 1.1. Main objective: Compare the hemodynamic effects from invasive systolic diastolic and mean blood pressures (ISBP, IDBP and IMBP) mesured in mmHg, arterial partial pressure of oxygen (PaO2) and arterial partial pressure of carbon dioxide (PaCO2) measured in mmHg , arterial oxygen saturation (SatO2) measured in%, heart rate (HR / bpm) measured in beats per minute. Other variables of interest will be: cardiac index (CI) mesured in litres per minute per square metre (L/min/m2), peripheral vascular resistance (PVR) medured in dynes/seconds/cm-5, partial arterial pressure of oxygen (PaO2) and arterial partial pressure of carbon dioxide (PaCO2) measured in mmHg, pH (pH), arterial lactate (Lc) measured in mmol / L, arterial hemoglobin (Hb) measured in g/dl, partial oxygen saturation (SpO2%) measured in %. 1.2. Secondary objectives: Assess potential adverse events during surgery and 48 hours of surgery. Adverse events include adverse cardiovascular and respiratory rate, events related to both surgical and anesthetic techniques and exitus. End points 2.1. Primary end point(s): hemodynamic variables invasive systolic blood pressure (ISBP) measured in mmHg invasive diastolic blood pressure (ISBP), measured in mmHg invasive mean blood pressure (IMBP), measured in mmHg arterial partial pressure of oxygen (PaO2) arterial partial pressure of carbon dioxide (PaCO2), measured in mmHg arterial oxygen saturation (SatO2) measured in% heart rate (HR / bpm) measured in beats per minute cardiac index (CI) mesured in litres per minute per square metre (L/min/m2). peripheral vascular resistance (PVR) mesured in dynes/seconds/cm-5 partial arterial pressure of oxygen (PaO2) measured in mmHg arterial partial pressure of carbon dioxide (PaCO2) measured in mmHg pH (pH) arterial lactate (Lc) measured in mmol / L arterial hemoglobin (Hb) measured in g / dl partial oxygen saturation (SpO2%) measured in %. 2.1.1 Timepoint(s) of evaluation of this end point: entry into the operating room, after 30 minutes of anesthesia and at the end of anesthesia. 2.2. Secondary end point(s): A. Intraoperative adverse events: Cardiovascular and Respiratory: Venous air embolism (VAE), deep vein thrombosis (DVT), myocardial infarction (AMI), cerebrovascular accident (CVA), congestive heart failure (CHF), pneumonia (N), Exitus (Ex) Other: Acute renal failure (ARF), vomiting (V) Associated with the surgical technique: RBC transfusion (Th), plasma transfusion (TPL), nerve damage (ln), femur fracture (Fx f) Associated with the anesthetic technique: paresthesia (pair), hematic puncture (ph), other. B.Postoperative adverse events (at 48 hours) Cardiovascular and Respiratory: Deep vein thrombosis (DVT), myocardial infarction (AMI), cerebrovascular accident (CVA), congestive heart failure (CHF), pneumonia (N), Exitus (Ex) Other: Acute renal failure (ARF), UTI (Infu), vomiting (V). Associated with the surgical technique: RBC transfusion (Th), plasma transfusion (TPL), neurologic deficit (defnq), surgical wound infection (Infhq). Associated with the anesthetic technique: neurological deficit (defn), postdural puncture headache (PDPH), back pain (Lumb). 2.2.1. Timepoint(s) of evaluation of this end point: 48 hours of surgery

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hip Fractures, Hemodynamic Stability
Keywords
Hip fracture, Subarachnoid block

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Levobupivacaine Hydrochloride 0,5%
Arm Type
Experimental
Arm Description
The doses used of Levobupivacaine Hydrochloride 0.5% will be 6 mg and the dose of fentanyl 10 μg.
Arm Title
isobaric bupivacaine 0,5%
Arm Type
Active Comparator
Arm Description
The doses used of isobaric bupivacaine will be 6 mg and the dose of fentanyl 10 μg.
Intervention Type
Drug
Intervention Name(s)
Levobupivacaine Hydrochloride 0.5%
Other Intervention Name(s)
L solution
Intervention Description
The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.
Intervention Type
Drug
Intervention Name(s)
Isobaric bupivacaine 0.5%
Other Intervention Name(s)
B solution
Intervention Description
The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
Primary Outcome Measure Information:
Title
Compare hemodynamic effects from invasive systolic pressure, invasive diastolic pressure and mean blood pressure.
Description
The measurement of invasive systolic pressure and invasive diastolic pressure and mean blood pressure mesured in mmHg.
Time Frame
Intraoperative
Title
Compare hemodynamic effects from heart rate.
Description
The measurement of heart rate in beats per minute.
Time Frame
Intraoperative
Secondary Outcome Measure Information:
Title
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Description
Adverse events include adverse cardiovascular and respiratory rate, events related to both surgical and anesthetic techniques.
Time Frame
48 hours of surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Maximum Age & Unit of Time
120 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and Women over 65 years Who meet the requirements in the pre-anesthetic to be treated with spinal anesthesia with levobupivacaine or bupivacaine, both with fentanyl, Fitness: from I to IV, according to the American Society of Anesthesiologists (ASA), Weight> 40 kg, Height> 140 cm, Body mass index (BMI) <50 kg/m2, Pathology cardiovascular, respiratory, renal and endocrine-metabolic, Provide written informed consent Exclusion Criteria: Patients with uncontrolled hypertension (non-invasive systolic blood pressure> 180 mmHg and / or non-invasive diastolic blood pressure > 110mmHg), HR> 120 bpm, SpO2 <90% on arrival in the operating room and the contraindication to perform neuraxial anesthesia (patient refusal, infection at the site of puncture or lancing different, neuromuscular degenerative disease, hypovolemia, coagulopathy or anticoagulant therapy, morbid obesity, and extreme increase in intracranial pressure).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
HERRERA Rosa, PhD
Phone
+34 659205338
Email
35606rhc@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
BELDA Fco Javier, Professor
Phone
+34 961.973.500
Ext
973847
Email
Fco.Javier.Belda@uv.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
HERRERA ROSA, PhD
Organizational Affiliation
General University Hospital of Valencia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Clínico Universitario
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
HERRERA ROSA, PhD
Phone
+34961.973.500
Email
35606rhc@gmail.com
First Name & Middle Initial & Last Name & Degree
TORNERO CARLOS, PhD
Phone
+34961.973.500
Email
carlos.tornero@uv.es

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Hemodynamic Safety of Levobupivacaine vs Bupivacaine in Patients Over 65 Years Undergoing Hip Surgery

We'll reach out to this number within 24 hrs